Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Clearside Biomedical, Inc.CLSD · Entity 82875 | Director | June 20, 2024 | June 21, 2024 |
| Opus Genetics, Inc.IRD · Entity 5892 | Director · President | July 23, 2026 | July 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Clearside Biomedical, Inc.
Report date June 20, 2024 · Filed June 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2034-06-19 | Direct | 45,000 |
Reported balance
After 2024-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 45,000 · Balance 45,000 F1: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2025, subject to the Reporting Person's continuous service as of such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2025, subject to the Reporting Person's continuous service as of such vesting date.
Opus Genetics, Inc.
Report date July 23, 2026 · Filed July 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 704,106 |
Reported balance
After 2026-07-23 transaction · row 1
1 source rowRow 1 · 2026-07-23 · Sale · Disposed 7,429 · Balance 704,106 F1: The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 23, 2026 Filed Jul 27, 2026 20:08 UTC | Opus Genetics, Inc. IRD · Entity 5892 | SaleCommon Stock | 7,429 | $2.97 | $22,064.13 |
DisclosureSEC source: 0000905148-26-003354 · form4.xml · nonDerivative · entry 1 YERXA BENJAMIN R · CIK 0001145910 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 704,106 F1 · kind: The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person. Read SEC document |
| April 23, 2026 Filed Apr 27, 2026 20:28 UTC | Opus Genetics, Inc. IRD · Entity 5892 | SaleCommon Stock | 7,470 | $5.24 | $39,121.14 |
DisclosureSEC source: 0000905148-26-001867 · form4.xml · nonDerivative · entry 1 YERXA BENJAMIN R · CIK 0001145910 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 711,535 F1 · kind: The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person. F2 · price: The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $5.2314 to $5.2413, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 22, 2026 Filed Jan 27, 2026 00:51 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 400,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-000359 · form4.xml · nonDerivative · entry 1 YERXA BENJAMIN R · CIK 0001145910 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 719,005 F1 · shares: Represents a grant of restricted stock units which vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen (16) quarters, subject to the Reporting Person's continuing service. Read SEC document |
| October 22, 2025 Filed Oct 24, 2025 20:16 UTC | Opus Genetics, Inc. IRD · Entity 5892 | Tax withholdingCommon Stock | 23,795 | $1.95 | $46,400.25 |
DisclosureSEC source: 0000905148-25-003670 · form4.xml · nonDerivative · entry 1 YERXA BENJAMIN R · CIK 0001145910 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 319,005 Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 21:18 UTC | Opus Genetics, Inc. IRD · Entity 5892 | PurchaseCommon Stock | 10,000 | $0.98 | $9,834.00 |
DisclosureSEC source: 0000905148-24-003268 · form4.xml · nonDerivative · entry 1 YERXA BENJAMIN R · CIK 0001145910 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 342,800 Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 21:35 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 332,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-003015 · form4.xml · nonDerivative · entry 1 YERXA BENJAMIN R · CIK 0001145910 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 332,800 F1 · shares: Represents a grant of restricted stock units which vest in four equal installments on the first, second, third, and fourth anniversary of October 22, 2024, subject to the Reporting Person's continuing service. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 20:15 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001415889-24-017826 · form4-06212024_040616.xml · derivative · entry 1 YERXA BENJAMIN R · CIK 0001145910 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2025, subject to the Reporting Person's continuous service as of such vesting date. Read SEC document |
| May 15, 2024 Filed May 15, 2024 21:28 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | PurchaseCommon Stock | 7,813 | $1.31 | $10,235.03 |
DisclosureSEC source: 0001415889-24-013248 · form4-05152024_090534.xml · nonDerivative · entry 1 YERXA BENJAMIN R · CIK 0001145910 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,957 Read SEC document |
| June 22, 2023 Filed Jun 23, 2023 20:36 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001209191-23-039416 · doc4.xml · derivative · entry 1 YERXA BENJAMIN R · CIK 0001145910 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 22, 2024, subject to the Reporting Person's continuous service as of such vesting date. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 20:27 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001209191-22-039237 · doc4.xml · derivative · entry 1 YERXA BENJAMIN R · CIK 0001145910 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-06-21 F1 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 22, 2023. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 22:09 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.49 | $0.00 |
DisclosureSEC source: 0001209191-22-016390 · doc4.xml · derivative · entry 1 YERXA BENJAMIN R · CIK 0001145910 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-03-02 F1 · derivative.exercise_date: This option will vest and become exercisable in 36 equal monthly installments beginning on April 2, 2022, subject to the Reporting Person's continuous service as of such vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.